Related references
Note: Only part of the references are listed.STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion
Chuan-xia Zhang et al.
CELL DEATH AND DIFFERENTIATION (2019)
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Triparna Sen et al.
CANCER DISCOVERY (2019)
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients
Ryan J. Sullivan et al.
NATURE MEDICINE (2019)
STING: a master regulator in the cancer-immunity cycle
Yuanyuan Zhu et al.
MOLECULAR CANCER (2019)
The STING ligand cGAMP potentiates the efficacy of vaccine-induced CD8+ T cells
Alice Gutjahr et al.
JCI INSIGHT (2019)
Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis
Tamer B. Shabaneh et al.
CANCER RESEARCH (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Priming of dendritic cells by DNA-containing extracellular vesicles from activated T cells through antigen-driven contacts
Daniel Torralba et al.
NATURE COMMUNICATIONS (2018)
Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition
Douglas B. Johnson et al.
JOURNAL OF IMMUNOTHERAPY (2017)
In situ click chemistry generation of cyclooxygenase-2 inhibitors
Atul Bhardwaj et al.
NATURE COMMUNICATIONS (2017)
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Hiro Sato et al.
NATURE COMMUNICATIONS (2017)
Molecular Pathways: Targeting the Stimulator of InterferonGenes(STING) in the Immunotherapyof Cancer
Leticia Corrales et al.
CLINICAL CANCER RESEARCH (2015)
Protamine-oligonucleotide-nanoparticles: Recent advances in drug delivery and drug targeting
B. Scheicher et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma A Pooled Analysis of 4 Clinical Trials
James Larkin et al.
JAMA ONCOLOGY (2015)
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Seng-Ryong Woo et al.
IMMUNITY (2014)
Cationic liposome-nucleic acid complexes for gene delivery and gene silencing
Cyrus R. Safinya et al.
NEW JOURNAL OF CHEMISTRY (2014)
The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
Xiaofeng Jiang et al.
CLINICAL CANCER RESEARCH (2013)
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Lijun Sun et al.
SCIENCE (2013)
Lessons from Cancer Immunoediting in Cutaneous Melanoma
Mariana Aris et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Hard Times for Oncogenic BRAF-Expressing Melanoma Cells
Miles D. Houslay
CANCER CELL (2011)
PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
Kim H. T. Paraiso et al.
CANCER RESEARCH (2011)
BrafV600E cooperates with Pten loss to induce metastatic melanoma
David Dankort et al.
NATURE GENETICS (2009)
The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
Hidetoshi Sumimoto et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Share Paper
